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Abstract
Objective—To determine if salivary biomarkers demonstrate utility for identifying aspects of
myocardial necrosis.
Methods—Twenty-one patients undergoing alcohol septal ablation (ASA) for treatment of
hypertrophic cardiomyopathy provided serum and unstimulated whole saliva at baseline and
incremental time points post-ASA. Samples were analyzed for seven biomarkers related to
myocardial damage, inflammation and tissue remodeling using immunosorbent assays. Levels
were compared to baseline and levels observed in 97 healthy controls.
Results—Biomarkers of myocardial damage and inflammation (i.e., troponin I, creatine kinase-
MB, myoglobin, C-reactive protein) rose in serum 2 to 812-fold after ASA (p<0.01). Significant
elevations of 2 to 3.5-fold were observed with C-reactive protein and troponin I in saliva (p<0.02).
Significant correlations between levels in serum and saliva were observed for C-reactive protein,
matrix metalloproteinase-9, and myeloperoxidase (p < 0.001).
Conclusions—Select salivary biomarkers reflect changes that occur during, and subsequent to,
myocardial necrosis caused by ASA.
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Saliva is an oral fluid, composed mainly of water, produced and secreted in large part from
the acinar and ductal cells of the major and minor salivary glands. Whole saliva derives
additional constituents from serum, gingival crevicular fluid and oral mucosal transudate,
making it appealing as a potential diagnostic fluid reflective of circulating levels in blood.1
Several studies report systemic biomarkers appearing in saliva including electrolytes,2, 3
blood products,4 enzymes and tissue destruction molecules,5–9 inflammatory markers,10–16
as well as proteins putatively associated with deadly diseases.17–21 However, the clinical
utility of salivary diagnostics for the assessment of systemic disease remains elusive.20, 22–27
Cardiovascular disease (CVD) is a major cause of mortality in the U.S. and worldwide.
More than 17 million people died from CVD in 2008, with the majority due to
atherosclerotic events including myocardial infarction.28, 29 With the extend and importance
of this disease, easy, noninvasive and low cost screening methods for the detection of
myocardial infarction continue to be sought. One such potential screening fluid is saliva.30
Support for the use of saliva for the detection of CVD and myocardial infarction is built
upon the framework that many serum biomarkers associated with inflammation,
atherosclerosis, plaque stability and myocardial damage are known and appear in oral
fluids.4, 9, 31–35 However, only a limited number of studies have demonstrated correlations
between serum and salivary biomarkers of CVD.14, 33, 36 Thus, additional research is
required if we are to gain a greater understanding of the clinical utility of saliva compared to
serum with respect to CVD and myocardial infarction assessment. This is particularly
important for finding new diagnostics for situations where acquisition, processing or
analysis of blood is problematic.
In this research investigation, we hypothesized that select salivary biomarkers would
correlate with serum biomarkers of CVD in patients with pre-existing heart disease and
could yield important diagnostic information regarding the evolution and progression of
myocardial necrosis. To test this hypothesis we employed a unique model of myocardial
infarction in patients with a pre-existing CVD (i.e., hypertrophic cardiomyopathy [HCM])
who were scheduled to undergo alcohol septal ablation (ASA). This procedure results in a
controlled myocardial infarction and subsequent remodeling processes that permit improved
hemodynamics and improved patient outcomes.37, 38 Together, the pre-existing CVD and
subsequent kinetic course of myocardial necrosis allowed us to predict that a spectrum of
myocardial damage, inflammation and tissue remodeling biomarkers would appear in serum
and saliva at baseline, and significant spikes would occur in these biomarker levels during
the post-operative phase consistent with myocardial infarction.39–43 Here this unique study
design permitted us to report the novel findings that salivary levels of troponin (Tn)I and C-
reactive protein (CRP) reflected changes in serum consistent with myocardial damage, and
select salivary biomarkers correlate with serum biomarkers of CVD.
METHODS
Patients
Patients were eligible for study participation if they underwent ASA as treatment for HCM
at the University of Kentucky Chandler Medical Center between May 1, 2007 and May 31,
2011. The diagnosis of HCM was based on established clinical and echocardiographic
criteria. At our institution, ASA is performed for patients with HCM if they have severe
symptoms (dyspnea, New York Heart Association (NYHA) heart failure class III to IV,
Canadian Cardiovascular Society (CCS) anginal class 3 to 4, or recurrent exercise-induced
syncope and are refractory to medical therapy with left ventricular outflow tract gradients
(LVOT) at rest ≥30mmHg or with provocation ≥50mmHg. Exclusion criteria included age
less than 18 years, unable or unwilling to provide informed consent or provide samples,
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recently treated with chemotherapeutic drugs, anti-organ rejection drugs, or significant
immune modulators within the last 3 months or during the course of the study, febrile illness
or active infection at the time of enrollment, or were pregnant. Once screened, 21 patients
scheduled for echocardiography-guided ASA were enrolled. In addition, a cohort of healthy
subjects (i.e., their medical history was negative for CVD and any current or recent cardiac
symptoms) was recruited (n=97) to provide baseline comparative samples for study and to
validate that sample processing and storage did not produce unexpected abnormalities.
Written informed consent was obtained from all patients before their procedure. The study
was approved by the University’s Institutional Review Board. All study participants were
provided financial remuneration for their participation.
Catheter ablation
In all patients, arterial access was obtained from the femoral region and coronary
angiography was performed. A coronary guide catheter was positioned in the left main
coronary artery ostium and a guidewire was advanced into a proximal septal perforating
artery off the left anterior descending coronary artery. Definity® contrast (Lantheus Medical
Imaging, North Billerica, MA, USA) was injected during transthoracic echocardiography to
assess the localization and extent of the myocardial territory perfused by the target septal
branch. A coronary balloon was inflated at the origin of the septal branch and if no leakage
occurred and the perfused myocardial segment was considered responsible for the
occurrence of the LVOT gradient, approximately 1 mL of 96% ethanol was slowly injected
through the balloon into the vessel to be ablated. The balloon was deflated 5 minutes after
infusion of alcohol. This procedure was repeated in the same or additional septal perforators
until the LVOT gradient decreased to as low a gradient as possible, ideally zero mmHg.
After the procedure, patients were monitored for 72 hours to observe for potential adverse
events. Follow-up occurred in our cardiology clinic within the next two to four weeks where
repeat transthoracic echocardiography was performed.
Specimens
Serum and UWS samples were collected from each subject at baseline and at 8, 16, 24 and
48 hours post-procedure during times predicted to demonstrate myocardial injury,
inflammation and tissue remodeling. Unstimulated whole expectorated saliva (5 mL) was
collected at each increment according to a modification in the method described by
Navazesh.44 All baseline samples were collected between 8 a.m. and 6 p.m. Subjects rinsed
their mouth with tap water, then expectorated whole saliva into sterile tubes containing a
protease inhibitor solution (SIGMAFAST, Sigma, St. Louis, MO.) while seated in an upright
position. All samples were immediately placed on ice, transported to the laboratory on ice
within 10 minutes of collection, centrifuged, separated into aliquots and stored at −80°C
until analyzed.
Immunoassays
All samples (n=190 ablation and 194 control) were analyzed in duplicate within three
months of storage. Unpublished data from our lab indicate that levels of biomarkers are
consistently maintained when stored for three months at −80°C. Levels of the classic cardiac
biomarkers cardiac troponin (TnI), creatine kinase (CK)-MB, myoglobin (MYO) and B-type
natriuretic peptide (BNP) were analyzed using a Beckman Access in the hospital CLIA
certified laboratory. Concentrations of serum CRP, matrix metalloproteinase (MMP)-9,
myeloperoxidase (MPO) as markers of inflammation, tissue damage and remodeling were
determined in duplicate using Luminex® IS100-based multiplex kits (Millipore, St. Charles,
MO, USA) according to the manufacturer’s directions in the University of Kentucky Center
for Oral Health Research laboratory. Standards were included on all runs and all results are
reported within the linearity of the assays.
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Statistical analysis
Statistical analyses were performed using the PC SAS 9.2 (SAS Institute Inc., Cary, NC,
USA). Continuous demographic variables are presented as mean, standard deviations (SD),
and categorical demographic variables as frequencies and percentages. The interval level
variables were compared between patients and controls using two-sample t statistics while
categorical variables were compared between these two groups using a chi-square statistic or
Fisher’s exact test. Biomarker levels, both raw scale and log transformed, are presented as
mean and SD by visit time. Spearman’s correlations were determined for each biomarker in
saliva relative to serum at each time point. Biomarker levels were compared between each
follow-up time point and baseline using the Wilcoxon signed rank test, and between baseline
and the mean of the healthy control level using the Wilcoxon rank sum test. To control the
Type I error rate, statistical significance was determined at the p < 0.01 level with marginal
significance defined by p < 0.05.
RESULTS
Of 21 patients screened and enrolled, 19 provided samples and completed the study. Two
patients were excluded because their procedure was cancelled. Characteristics of the
participants are shown in Table 1. The majority were female, white and non-tobacco users.
All were Caucasian and used alcohol infrequently. The majority completed the study
without incident, although 8 of 19 patients developed complete heart block in the immediate
post-operative period that necessitated placement of a permanent pacemaker. The 97
controls were on average 10 years younger, more racially diverse, and used less tobacco, but
more alcohol than the ASA patients.
Myocardial necrosis biomarkers in serum and UWS
Serum markers of myocardial necrosis (TnI, CK-MB, and MYO) rose significantly after
alcohol infusion consistent with features of acute myocardial infarction (Fig. 1). Peak serum
levels were evident for MYO at 8 hours (11-fold increase compared to baseline), CK-MB at
8–16 hours (70-fold increase), and TnI at 16–24 hours (over 800-fold increase) (p<0.001,
respectively). Mean BNP levels at baseline were significantly above healthy control values
(p<0.001), and trended downward after 16 hours.
These same biomarkers showed elevated trends in saliva, although less dramatic (Fig. 2).
The mean level of salivary CK-MB drifted upward early (p>0.05) and returned to baseline
levels thereafter, and remained below healthy control levels at all time points. Salivary
MYO levels rose 2-fold above baseline 8 hours after the ablation and was significantly
above healthy control levels between 8 and 24 hours (p<0.01). Salivary TnI levels were
significantly lower than the mean of the healthy controls at baseline (p<0.004) and rose
significantly above baseline between 24 and 48 hours post-ASA (p<0.002). Levels of
salivary BNP, in contrast to serum BNP, were significantly lower than the mean of the
healthy controls at baseline, then trended upward after 16 hour to levels 2.3-fold above
baseline at 48 hours (p<0.02).
Biomarkers associated with inflammation, tissue injury and remodeling
Figure 3 shows that serum CRP rose after 8 hours to levels 3.6-fold above baseline at 48
hours (p<0.001). Salivary levels of CRP also trended upward during this time frame
compared with baseline (p<0.012). The remodeling biomarker MMP-9 and neutrophil
enzyme MPO rose early in serum, but were less than 2-fold above baseline at their peak
(p>0.05). In contrast, salivary levels of MMP-9 were elevated above baseline at 16 hours
(p<0.012), but remained below baseline and the mean control value thereafter. A downward
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trend was observed for salivary MPO that was significantly below baseline at 48 hours
(p=0.037).
Correlations of biomarkers in serum and saliva
To further investigate which salivary biomarkers demonstrated potential clinical utility,
Spearman correlations were computed with respect to the mean biomarker levels in serum
and saliva for each time point. Table 2 shows that the strongest correlations between fluids
occurred with CRP, MMP-9 and MPO. The correlation coefficients for MPO and MMP-9
were high and ranged between 0.68–0.90 for all time points (p<0.05 in each case). Salivary
CRP levels correlated well with serum CRP, with correlations being strongest at baseline, 8
and 48 hours (0.66–0.80, p<0.022). MYO also produced significant correlation at 16 hours
(r = 0.58, p = 0.04; not shown).
DISCUSSION
We examined the kinetics of serum and salivary biomarkers in patients with HCM following
ASA to help determine the clinical utility of salivary biomarkers with respect to CVD and
myocardial necrosis. This model provided several advantages for examining our hypothesis.
First, the introduction of alcohol during the ablation procedure produces myocardial necrosis
and an associated inflammatory response and tissue remodeling events.45–47 These events
produce elevations in the selected serum biomarkers that we hypothesized would appear in
saliva. Second, the use of the alcohol septal ablation as a “planned myocardial infarction”
provided the advantage of uniformity of timing and the ability to capture bodily fluids at
exact time points after the onset of myocardial necrosis.45–48 Finally, the model afforded the
opportunity to compare baseline levels of important CVD biomarkers in HCM with healthy
controls. Using this unique study design, we determined that significant differences in
biomarker levels in serum and saliva existed between healthy controls and patients with
HCM at rest. Also, we identified salivary biomarkers of potential utility for the diagnosis of
acute myocardial infarction, and perhaps determined insight into the “ischemic time”
amongst patients presenting with spontaneous myocardial infarction.
During the hours following the ablation we observed a classic rise in serum cardiac enzymes
consistent with the picture of spontaneous myocardial necrosis as observed by Hage et al.39
Hage et al. previously demonstrated that this rise in serum markers of myocardial damage
following ASA correlates with the size of myocardial infarction.39 Like Hage et al., we
observed that serum levels of TnI rose approximately 800-fold over baseline and CK-MB
rose about 70-fold post-ASA. We also observed the novel finding that MYO rose 11-fold
and was an early serum biomarker of myocardial damage post-ASA. Serum levels of CK-
MB peaked between 8 and 16 hour and TnI peaked at 24 hour. In comparison, the rise of
these biomarkers in saliva was less dramatic and required more time to become significantly
elevated above baseline. Here salivary levels of TnI and MYO were significantly elevated
above baseline and healthy control levels, respectively at 16 hour. Also, more than 70% of
the participants showed elevations in one or more of myonecrosis biomarkers (i.e., CK-MB,
MYO and TnI) in saliva in the post-operative phase (data not shown). Together these
findings suggest that as a salivary panel CK-MB, MYO and TnI may have utility in
screening for myocardial necrosis during situations when acquisition, processing or analysis
of blood is problematic such as in military field situations, primary care offices or
ambulances. In addition, a benefit of these studies could be the development of portable
diagnostic devices that would use small quantities of fluid such as either capillary blood or
saliva. Here future studies would establish which fluid demonstrates clinical utility for
optimal diagnostics.
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We also examined levels of CRP, MMP-9 and MPO. These biomarkers are associated with
inflammation, tissue damage and tissue remodeling during and/or subsequent to myocardial
infarction. Specific to our study design, serum levels of CRP, MMP-9 and MPO have shown
significant elevations during the first 48 hours after a myocardial infarction.49–52 In our
study, serum and salivary levels of CRP demonstrated changes in concentrations in serum
after the ablation procedure. Serum CRP levels rose significantly and progressively
suggestive of the myocardial infarction49 and ongoing inflammation that occurs post-
ablation. Salivary CRP levels also rose significantly post-ablation, however the increase in
concentrations observed were less than those that occurred in serum. After the first 8 hours
following ASA, downward trends were observed with levels of MMP-9 and MPO in both
serum and saliva suggestive of the relationship between concentrations in both fluids and the
nadir that occurs around 48 hours for these two biomarkers.51, 52
Time point correlations were examined in an effort to determine which salivary biomarkers
correlated best with serum levels during the 48 hours following ASA. Here salivary levels of
CRP, MMP-9, and MPO showed impressive correlations with serum levels, both before and
after the invasive procedure. Consistent with our observation, Ouellet-Morin et al. showed a
correlation between CRP levels measured in serum and saliva,14 however this observation
was not noted by Dillon et al.34 Our correlation between salivary and serum levels of
MMP-9 as well as salivary and serum levels of MPO appears to be the first report of these
findings. MMP-9 is known to be associated with collagen remodeling,46 and CRP and MPO
have been shown to be important for predicting risk of CV mortality.47 Thus, levels of these
three biomarkers alone, or in combination, in saliva may provide insight into serum levels as
well as the evolving kinetics following the initiation of myocardial necrosis.
A limited number of other serum CVD biomarkers have been reported to correlate with
salivary concentrations.35 Mirzaii-Dizgah et al. reported correlations between serum and
salivary creatine phosphokinase and serum and salivary CK-MB concentrations in two
studies of 30 acute myocardial infarction patients.33, 36 In our study, salivary levels of CK-
MB did not correlate with serum levels, and salivary CK-MB levels rose only about 0.4-fold
above baseline at 16 hour post-ablation. Although it is not completely clear why there is a
discrepancy between our findings and those of Mirzaii-Dizgah et al., it is possible that the
small number of patients enrolled in both studies is a factor, or differing demographics and
methodologies influenced the outcomes. Alternatively, it is possible that the release kinetics
of myonecrosis biomarkers may differ following an infarction caused by alcohol infusion
compared to the thromboembolic occlusion of a spontaneous myocardial infarction, however
existing evidence suggests that they demonstrate several similarities.45, 46
In conclusion, we observed 1) a significant change in concentrations in salivary TnI and
CRP compared with baseline post-ASA, 2) three CVD biomarkers (CRP, MMP-9 and MPO)
in saliva correlate with serum levels, 3) six of seven biomarkers moved temporally in the
same direction as those observed in serum, and 4) several of the biomarker levels changed
within the first 24 hour post-ablation. These data suggest that a diagnostic window exists in
which saliva may have utility for screening for myocardial infarction. Future studies are
needed that include larger patient populations to help advance these findings and for the
development of salivary diagnostic devices for potential screening of CVD as an alternative
or complement to blood in situations where acquisition, processing or analysis of blood is
problematic. Inclusion of large populations should help define the concentration ranges
displayed during health versus disease as well as the composition of the biomarker panel
needed to provide accurate interpretation of the results.
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Clinical Relevance
Although serum biomarkers remain the gold standard for the assessment of acute
myocardial infarction, these findings demonstrate saliva’s potential for providing
additional diagnostic information with respect to myocardial infarction.
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Figure 1.
Serum markers of myocardial damage. Mean concentrations and standard deviations shown
of A) CK-MB, B) MYO, C) TnI and D) BNP shown at 0, 8, 16, 24 and 48 hr. Mean healthy
control levels shown as dashed lines with standard deviation shown as gray boxes. The red
asterisk indicates levels are significantly different from baseline (p<0.002) in panels A, B
and C, and a black asterisk indicates levels are different from baseline (p=0.02) in panel D.
The red † indicates levels are significantly different from healthy controls at baseline
(p<0.01).
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Figure 2.
Salivary biomarkers of myocardial damage. Mean concentrations and standard deviations
shown of A) CK-MB, B) MYO, C) TnI, and D) BNP. Mean healthy control levels shown as
dashed lines with standard deviation shown as gray boxes. Black asterisk indicates levels are
different from baseline (p<0.02). The red asterisk indicates levels are significantly different
from baseline (p<0.01). The red † indicates levels are significantly different from healthy
control levels (p<0.01). In panel D, the standard deviation of the healthy controls has been
truncated; the lower limit is −40
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Figure 3.
Biomarkers of inflammation, tissue injury and tissue remodeling. Mean concentrations and
standard deviations shown at 0, 8, 16, 24 and 48 hr. A) serum CRP, B) serum MMP-9, C)
serum MPO, D) salivary CRP, E) salivary MMP-9 and F) salivary MPO. Mean healthy
control levels shown as dashed lines with standard deviation shown as gray boxes. Black
asterisk indicates levels are different from baseline (p≤0.04). The red asterisk indicates
levels are significantly different from baseline (p<0.01).
Foley et al. Page 13
Oral Surg Oral Med Oral Pathol Oral Radiol. Author manuscript; available in PMC 2013 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Foley et al. Page 14
Table 1
Demographics of study population.
Ablation Controls
N=19 N=97
Age (yrs; mean +/− SD) 58.58 +/− 13.41 48.6 +/− 8.6*
Female (%) 63.2 60.8
White (%) 100 86.6
African American (%) 0 8.2
Other races 0 5.2
Current Tobacco Use (%) 47.4 22.7*
Current Alcohol Use (%) 10.5 22.7*
Previous MI (%) 15.8 0*
*p <0.05
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Table 2
Biomarkers displaying correlations between serum and saliva levels at multiple time points.
Biomarker Hour r P value
CRP
0 0.80 <0.0001
8 0.71 0.0217
16 0.49 0.0899
24 0.52 0.0491
48 0.66 0.0108
MMP-9
0 0.78 0.0001
8 0.68 0.0424
16 0.76 0.0045
24 0.74 0.0027
48 0.71 0.0067
MPO
0 0.72 0.0012
8 0.85 0.0016
16 0.90 <0.0001
24 0.73 0.0030
48 0.86 0.0001
r = correlation coefficient
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